Vyepti (eptinezumab-jjmr) is Lundbeck’s CGRP antibody for migraine prevention, and it is the only one in its class given as an intravenous infusion rather than a self-injected pen. FDA labeling calls for 100 mg every 3 months, with 300 mg every 3 months as an option, delivered over roughly 30 minutes from a 100 mg/mL single-dose vial.
That route changes the entire pricing conversation. Vyepti is not dispensed at a pharmacy counter, so there is no cash price to look up, no discount card that touches it, and no coupon at the register. It is bought by the clinic, billed under a medical benefit as HCPCS code J3032, and the infusion itself is billed separately. A self-pay patient gets two bills, and most price pages only tell you about one of them. Every figure below was verified on September 1 and 2, 2026.
What Does Vyepti Cost Without Insurance?
There is no published national cash price for Vyepti, so the honest way to price it is against the two benchmarks that do exist: what the manufacturer sells it for, and what Medicare pays for it. Lundbeck’s Colorado pricing disclosure, a document the company is required to publish under state law, states a wholesale acquisition cost of $2,066.22 for one 100 mg/mL single-dose vial as of July 2026. CMS’s Medicare Part B payment limit file, effective July 1 through September 30, 2026, sets J3032 at $21.101 per mg, which is $2,110.10 for a 100 mg dose. Those two independent sources land within 2 percent of each other.
| Line item | Low | Typical | High |
|---|---|---|---|
| Vyepti 100 mg, drug only | $2,066.22 (Lundbeck list price) | $2,088.16 | $2,110.10 (Medicare payment limit) |
| Vyepti 300 mg, drug only (3 vials) | $6,198.66 | $6,264.48 | $6,330.30 |
| Infusion administration (CPT 96365) | $60.45 (Medicare allowed, office) | $217.31 (hospital outpatient rate) | $222.72 (average submitted charge) |
| One 100 mg infusion, both bills | $2,126.67 | $2,305.47 | $2,332.82 |
| Per-month equivalent, 100 mg every 3 months | $708.89 | $768.49 | $777.61 |
| Full year, four 100 mg infusions | $8,506.68 | $9,221.88 | $9,331.28 |
| Full year, four 300 mg infusions | $25,036.44 | $25,927.16 | $26,212.08 |
| Medicare Part B, average spend per patient per year (2024) | $11,048.97 | $11,048.97 | $11,048.97 |
| Lundbeck Migraine Patient Assistance Program (income-qualified, uninsured) | $0 | $0 | $0 |
The Medicare row is a useful reality check on the arithmetic above. CMS’s Medicare Part B Spending by Drug file for data year 2024, released June 25, 2026, records $70,625,021 in total spending on eptinezumab across 6,392 beneficiaries, which is $11,048.97 per beneficiary for the year at an average of $17.92 per milligram. That sits above the four-infusion 100 mg estimate and well below the 300 mg one, which is exactly what a real-world mix of the two doses should produce.
What Drives the Price
It is a buy-and-bill medical benefit, not a pharmacy benefit. This is the structural fact behind everything else. The clinic buys the vials, stocks them, and bills your visit afterward. That means no pharmacy price to shop, no GoodRx or SingleCare page that helps, and no way to price the treatment before you show up unless you ask for a written estimate.
Where the infusion happens. For the identical infusion code, CMS’s CY2026 hospital outpatient rate under January 2026 OPPS Addendum B is $217.31, while the average Medicare allowed amount in the physician-office setting in 2024 was $60.45. That is roughly a 3.6-fold difference for the same 30 minutes of nursing time, driven by hospital facility payment rules rather than by anything about the care.
The gap between what is billed and what is paid. CMS’s 2024 physician claims data shows an average submitted charge of $222.72 for CPT 96365 in the office setting against that $60.45 average allowed amount. Providers bill roughly 3.7 times what Medicare pays. Self-pay patients are the ones most likely to be quoted the billed number rather than the allowed number, and that gap is the whole reason a self-pay negotiation is worth having.
Which dose you are on. The 300 mg dose is literally three vials, so the drug half of the bill triples to roughly $6,199 to $6,330 while the administration half stays flat. There is no volume discount built into the pricing.
Dosing frequency works in your favor. Every 3 months is the single most important cost feature of this drug. A per-infusion figure over $2,000 looks alarming until you divide it by three months, at which point Vyepti’s drug cost lands in a similar monthly band to the self-injected CGRP antibodies rather than far above them.
Cash Price vs. Insurance
For an infused biologic, using insurance is almost always right if you have it. There is no cash-pay channel that undercuts the medical benefit, no manufacturer direct-purchase program, and no pharmacy to shop against. Paying cash here means paying a provider’s chargemaster rate for a drug the provider bought at or near the list price above.
If you are uninsured, the practical question is not “cash or insurance” but “what will you accept.” Because Vyepti has a hard acquisition cost the clinic actually paid, a self-pay quote is negotiable in a way that a pharmacy price is not. The clinic knows it paid roughly $2,066 for the vial. Anchoring a conversation to that number plus a reasonable administration fee is a far stronger position than asking for a percentage off an unexplained total.
Ask for the estimate in writing, with the J3032 drug line and the CPT 96365 administration line broken out separately and the place-of-service code stated. If a hospital is involved, its price-transparency file should contain both codes; our guide to hospital price transparency explains how to find and read that file before your appointment.
How to Pay Less
Apply to Lundbeck’s patient assistance program first. Lundbeck runs a Migraine Patient Assistance Program that supplies branded product to patients who live in the U.S. or a territory, hold a valid prescription for a covered product, have no prescription coverage for it, and can document financial need. Product ships to the provider rather than to the patient. Lundbeck does not publish an income threshold, so the only way to know is to apply.
Do not count on the copay card if you are uninsured. VYEPTI CONNECT advertises “as little as $0 per infusion” plus up to $200 toward administration costs per treatment, but Lundbeck’s posted eligibility requires commercial insurance coverage for Vyepti and excludes anyone enrolled in Medicare, Medicaid or another government program. If you have no coverage at all, this program is not available to you. The $200 administration allowance is still informative: it tells you roughly what the manufacturer expects that second bill to be.
Ask to be infused somewhere other than a hospital outpatient department. The $60.45 versus $217.31 gap above is the single easiest saving available on this treatment, and it is a scheduling question, not a clinical one. Freestanding infusion centers and neurology offices bill the administration without a hospital facility fee.
Get an itemized bill and check every line. Infusion visits accumulate charges that have nothing to do with the drug: saline, tubing, an office visit code, sometimes an observation charge. Our walkthrough on reading an itemized hospital bill covers how to request one and what to challenge.
Negotiate the balance rather than paying it. A four-figure infusion bill is the classic case for a written self-pay reduction request. Start with our negotiation script and the fuller guide to negotiating medical bills.
If a nonprofit hospital did the infusion, apply for charity care. Nonprofit hospitals are required to maintain financial assistance policies, and infusion charges are eligible like any other. See hospital charity care for who qualifies and how far back you can apply.
How Vyepti Compares to the Other CGRP Preventives
Vyepti is one of four CGRP antibodies approved for migraine prevention, and the only infused one. The other three are self-injected at home, which removes the administration bill entirely and puts them in a pharmacy channel where manufacturer savings programs and cash-pay options behave normally. For those prices, see Emgality cost, Ajovy cost and Aimovig cost.
If prevention is out of reach without coverage, the acute side of the budget is where most uninsured patients end up. Generic sumatriptan tablets cost pennies per dose, and the branded oral alternatives are priced in Nurtec cost and Qulipta cost.
Bottom Line
Vyepti costs roughly $2,127 to $2,333 per 100 mg infusion without insurance as of September 2026, or about $709 to $778 a month once you spread it across the every-3-months schedule. The number that surprises people is not the drug price, which two independent sources put at $2,066 to $2,110 per vial, but the fact that a second bill for the infusion itself arrives alongside it, and that the size of that second bill depends almost entirely on which building you sit in. Ask where the infusion will happen, ask for both line items in writing, and apply to Lundbeck’s assistance program before you agree to anything.